Clinical Trials Sponsored by Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.

Total 566 results

Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2)

Cellulite

United States
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1)

Cellulite

United States
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas

Dercum's Disease

United States
Tasly Biopharmaceuticals Co., Ltd.

Recruiting

A Trial to Evaluate the Safety Tolerability and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy Subjects

Nonalcoholic Steatohepatitis

United States
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)

Subcutaneous Fat

Australia
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)

Subcutaneous Fat

United States, Australia
Tasly Biopharmaceuticals Co., Ltd.

Completed

A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism (ERUPTE)

Acute Pulmonary Embolism

China
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat

Subcutaneous Fat

Australia
Caliway Biopharmaceuticals Co., Ltd.

Recruiting

A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.

Subcutaneous Fat

United States
Tasly Biopharmaceuticals Co., Ltd.

Active, not recruiting

rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2) (PROST-2)

Acute Ischemic Stroke

China
Caliway Biopharmaceuticals Co., Ltd.

Active, not recruiting

A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat

Subcutaneous Fat

United States
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers

Subcutaneous Fat

United States
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers

Subcutaneous Fat

Australia
Tasly Biopharmaceuticals Co., Ltd.

Completed

Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST)

Acute Ischaemic Stroke

China
Tasly Biopharmaceuticals Co., Ltd.

Completed

Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled Trial (PROUD)

Acute Ischaemic Stroke

China
Biocity Biopharmaceutics Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease

Diabetic Kidney Disease | IgA Nephropathy

China
Biocity Biopharmaceutics Co., Ltd.

Not yet recruiting

SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer

Advanced Ovarian Cancer | Serous Ovarian Cancer
Biocity Biopharmaceutics Co., Ltd.

Recruiting

A Phase I Study of BC3402 as a Single Agent in Patients With MDS and CMML

Hematologic Malignancy

China
Biocity Biopharmaceutics Co., Ltd.

Not yet recruiting

BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Biocity Biopharmaceutics Co., Ltd.

Recruiting

Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML

Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

China
Biocity Biopharmaceutics Co., Ltd.

Recruiting

Study of BC3195 Monotherapy in Patients With Advanced Solid Tumors (BC3195)

Locally Advanced or Metastatic Solid Tumors

China
Biocity Biopharmaceutics Co., Ltd.

Recruiting

SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Small Cell Lung Cancer

China
SUNHO（China）BioPharmaceutical CO., Ltd.

Not yet recruiting

A Clinical Trial to Evaluate Effect of IBD0333 in Patients With Advanced Malignant Tumors

MTD
Bliss Biopharmaceutical (Hangzhou) Co., Ltd

Recruiting

A First-in-human of Multiplle Doses of BB-1709 in Subjects With Locally Advanced/Metastatic Solid Tumors

Solid Tumor

China
Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Not yet recruiting

Phase III Study of GR1802 Injection in Patients With Atopic Dermatitis

Atopic Dermatitis

China
Curon Biopharmaceutical (Shanghai) Co.,Ltd

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN201

Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

China
FutureGen Biopharmaceutical (Beijing) Co., Ltd

Recruiting

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Locally Advanced Unresectable or Metastatic Gastric Cancer | Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

China
Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Not yet recruiting

The Study of Long-term Outcomes of GR1802 in Patients With Chronic Rhinosinusitis With Nasal Polyps

Chronic Rhinosinusitis With Nasal Polyps
Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Recruiting

Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE

Lupus Erythematosus, Systemic

China
Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Recruiting

The Study of Single Dose Administration of GR2002 Injection in Chinese Health Volunteers

Asthma

China
Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Recruiting

The Study of GR1802 in Patients With Chronic Rhinosinusitis With Nasal Polyps

Chronic Rhinosinusitis With Nasal Polyps

China
Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Recruiting

Study to Evaluate GR1801's Efficacy and Safety

Rabies Post-exposure Prophylaxis

China
SUNHO（China）BioPharmaceutical CO., Ltd.

Recruiting

To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Metastatic Colorectal Cancer

HER2 Gene Mutation

China
Curon Biopharmaceutical (Shanghai) Co.,Ltd

Recruiting

A Phase Ib/II Study of CN201 in Precursor B-cell Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

China
SUNHO（China）BioPharmaceutical CO., Ltd.

Recruiting

A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors

Advanced Malignant Tumors

China
Bliss Biopharmaceutical (Hangzhou) Co., Ltd

Recruiting

A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors

Solid Tumor

China
SUNHO（China）BioPharmaceutical CO., Ltd.

Recruiting

Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors

Advanced Solid Tumor

China
FutureGen Biopharmaceutical (Beijing) Co., Ltd

Recruiting

Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China

Advanced Unresectable Solid Tumors

China
Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Completed

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults

Tetanus

China
Shanghai Huaota Biopharmaceutical Co., Ltd.

Completed

A Study to Evaluate Multi-dose of HB0034 in Healthy Adult Participants

Healthy

New Zealand
Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Completed

to Evaluate the Preliminary Efficacy and Safety of GR1501 Injection in Patients With Active Axial Spondyloarthritis

Axial Spondyloarthritis

China
Shanghai Huaota Biopharmaceutical Co., Ltd.

Completed

A Study to Evaluate HB0034 in Healthy Adult Participants

Healthy

New Zealand
Tasly Tianjin Biopharmaceutical Co., Ltd.

Unknown

Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) Combined With Nucleoside (Acid) Analogues in Chronic Hepatitis B Patients

Hepatitis B Virus (HBV)

China
Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).

Allergic Rhinitis
SUNHO（China）BioPharmaceutical CO., Ltd.

Not yet recruiting

A Study of IAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder Cancer

Bladder Cancer
Suzhou Kanova Biopharmaceutical Co., LTD

Not yet recruiting

Phase I of XKH002 Injection in Patients

Advanced or Metastatic Solid Tumors
SUNHO（China）BioPharmaceutical CO., Ltd.

Recruiting

A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors

Advanced Malignant Tumors

China
Beijing QL Biopharmaceutical Co.,Ltd

Enrolling by invitation

A Study of ZT002 Injection in Participants With Overweight or Obesity

Overweight or Obesity

China
Shanghai Ark Biopharmaceutical Co., Ltd.
Shanghai Ark Biopharmaceutical Co., Ltd.

Completed

A Study of AK0529 in Chinese Infants Hospitalized With RSV (AIRFLO)

Respiratory Syncytial Virus Infections

China
Tasly Tianjin Biopharmaceutical Co., Ltd.

Unknown

Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors

Advanced Malignant Solid Tumors

China

3

Subscribe